Abstracts Archive - Page 1135 of 2425 - ACR Meeting Abstracts

Abstract Number: 1956 • 2018 ACR/ARHP Annual Meeting
Cohort Effects in Back Pain: The Effect of Changes in Life-Style and Co-Occurring Conditions
Elizabeth M. Badley^1,2, Anthony V. Perruccio² and Mayilee Canizares², ¹Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ²Arthritis Program, Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: The goal of this study was to determine a) if the age-trajectory (life course) of back pain differs by birth cohort and b) whether…
Abstract Number: 1957 • 2018 ACR/ARHP Annual Meeting
Peri-Operative Glycemic Evaluation Prior to Total Joint Replacement in Patients with and without Diabetes
Lindsey A. MacFarlane¹, Yinzhu Jin², Patricia D. Franklin³, Joyce Lii⁴, Jeffrey N. Katz⁵ and Seoyoung C. Kim⁶, ¹Rheumatology, Brigham & Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worchester, MA, ⁴Brigham and Women'a Hospital, Boston, MA, ⁵Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁶Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Elevated hemoglobin A1c (HbA1c) has been associated with a 9-fold increase in wound complications after total joint replacement (TJR). Data suggest that including HbA1c…
Abstract Number: 1958 • 2018 ACR/ARHP Annual Meeting
Gene Expression Pathways across Multiple Tissues in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Reveal Core Pathways of Disease Pathology
Marcia Friedman¹, Donseok Choi^1,2,3,4, Steven Planck^1,4, James T. Rosenbaum⁵ and Cailin Sibley¹, ¹Oregon Health & Science University, Portland, OR, ²OHSU-PSU School of Public Health, Portland, OR, ³Graduate School of Dentistry, Kyung Hee Universtiy, Seoul, Korea, Republic of (South), ⁴Casey Eye Institute, Portland, OR, ⁵Ophthalmology, Oregon Health & Science University and Legacy Devers Eye Institute, Portland, OR
Background/Purpose: In recent years, several studies have characterized the gene expression signatures of different tissues affected by ANCA-associated vasculitis (AAV). The purpose of this study…
Abstract Number: 1959 • 2018 ACR/ARHP Annual Meeting
Stability of DNA Methylation Signature in Primary RA Synovial Fibroblasts Compared with Cultured Fibroblast-like Synoviocytes
Rizi Ai¹, Deepa Hammaker², Wei Wang³ and Gary S. Firestein⁴, ¹University of California San Diego, La Jolla, CA, ²Medicine, UC San Diego, La Jolla, CA, ³Chemistry and Biochemistry, University of California San Diego, La Jolla, CA, ⁴Medicine, University of California San Diego, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) is an aggressive immune-mediated joint disease with synovial inflammation and joint destruction. Fibroblast-like synoviocytes (FLS) play a key role in mediating…
Abstract Number: 1960 • 2018 ACR/ARHP Annual Meeting
Exome Sequencing Reveals Rare Recessive Mutations in Multiple Genes Including FAS, RAD51B, and ISG15 in a Single Family with Lupus and Suggests a Unique Genetic Model
Jessie Alperin¹, Khader Mustafa², Ola Hijjawi², Patrick Coit³, Kenneth Kaufman⁴ and Amr H Sawalha³, ¹University of Michigan Medical System, Ann Arbor, MI, ²Division of Rheumatology, The University of Jordan, Amman, Jordan, ³Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Lupus is a complex heterogeneous disease, which can affect almost any organ system. The genetic etiology of lupus is complex, with multiple genetic susceptibility…
Abstract Number: 1961 • 2018 ACR/ARHP Annual Meeting
Association of GTF2I Region Polymorphism with Systemic Lupus Erythematosus and Systemic Sclerosis, but Not with ANCA-Associated Vasculitis and Polymyositis/Dermatomyositis, in a Japanese Population
Nozomi Yokoyama^1,2, Aya Kawasaki^1,2, Takashi Matsushita³, Hiroshi Furukawa^1,2,4, Yuya Kondo⁵, Fumio Hirano^6,7, Ken-ei Sada⁸, Isao Matsumoto⁵, Makio Kusaoi⁹, Hirofumi Amano⁹, Shohei Nagaoka¹⁰, Keigo Setoguchi¹¹, Tatsuo Nagai¹², Kota Shimada^4,13, Shouji Sugii¹⁴, Atsushi Hashimoto¹⁵, Toshihiro Matsui¹⁶, Akira Okamoto¹⁷, Noriyuki Chiba¹⁸, Eiichi Suematsu¹⁹, Shigeru Ohno²⁰, Masao Katayama²¹, Kiyoshi Migita²², Hajime Kono²³, Minoru Hasegawa²⁴, Shigeto Kobayashi²⁵, Hidehiro Yamada²⁶, Kenji Nagasaka²⁷, Takahiko Sugihara²⁸, Kunihiro Yamagata²⁹, Shoichi Ozaki²⁶, Manabu Fujimoto³⁰, Naoto Tamura⁹, Yoshinari Takasaki⁹, Hiroshi Hashimoto³¹, Hirofumi Makino³², Yoshihiro Arimura³³, Masayoshi Harigai³⁴, Shinichi Sato³⁵, Takayuki Sumida⁵, Shigeto Tohma^36,37, Kazuhiko Takehara³ and Naoyuki Tsuchiya^1,2, ¹University of Tsukuba, Graduate School of Comprehensive Human Sciences, Masters' Program in Medical Sciences, Tsukuba, Japan, ²University of Tsukuba, Faculty of Medicine, Molecular and Genetic Epidemiology Laboratory, Tsukuba, Japan, ³Kanazawa University, Department of Dermatology, Kanazawa, Japan, ⁴National Hospital Organization Sagamihara l Hospital, Clinical Research Center for Allergy and Rheumatology, Sagamihara, Japan, ⁵Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁶Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Department of Rheumatology, Tokyo, Japan, ⁷Tokyo Medical and Dental UniversityGraduate School of Medical and Dental Sciences, Department of Lifetime Clinical Immunology, Tokyo, Japan, ⁸Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama, Japan, ⁹Juntendo University, School of Medicine, Department of Internal Medicine and Rheumatology, Tokyo, Japan, ¹⁰Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, ¹¹Allergy and Immunological Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan, ¹²Kitasato University, Department of Rheumatology and Infectious Diseases, Sagamihara, Japan, ¹³Department of Rheumatology, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan, ¹⁴Department of Rheumatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ¹⁵Rheumatology, National Hospital Organization Sagamihara Hospital, Sagamihara, Japan, ¹⁶National Hospital Organization Sagamihara l Hospital, Clinical Research Center for Allergy and Rheumatology, Kanagawa, Japan, ¹⁷Department of Rheumatology, Himeji Medical Center, National Hospital Organization, Himeji, Japan, ¹⁸Department of Rheumatology, Morioka Hospital, National Hospital Organization, Morioka, Japan, ¹⁹Clinical Research Institute, Department of Internal Medicine and Rheumatology, Kyushu Medical Center, National Hospital Organization, Fukuoka, Japan, ²⁰Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan, ²¹Department of Internal Medicine, Nagoya Medical Center, National Hospital Organization, Nagoya, Japan, ²²Fukushima Medical University, School of Medicine, Fukushima, Japan, ²³Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ²⁴University of Fukui, Department of Dermatology, Fukui, Japan, ²⁵Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, ²⁶St. Marianna University, School of Medicine, Department of Internal Medicine, Kawasaki, Japan, ²⁷Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ²⁸Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ²⁹University of Tsukuba, Faculty of Medicine, Department of Nephrology, Tsukuba, Japan, ³⁰University of Tsukuba, Faculty of Medicine, Department of Dermatology, Tsukuba, Japan, ³¹Juntendo University School of Medicine, Tokyo, Japan, ³²Okayama University Hospital, Okayama, Japan, ³³Kyorin University School of Medicine, First Department of Internal Medicine, Tokyo, Japan, ³⁴Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan, ³⁵The University of Tokyo, Department of Dermatology, Tokyo, Japan, ³⁶National Hospital Organization Tokyo National Hospital, Kiyose, Japan, ³⁷National Hospital Organization Tokyo Hospital, Sagamihara, Japan
Background/Purpose: Genome-wide association studies of systemic lupus erythematosus (SLE) in Chinese and Korean populations identified striking association with a single nucleotide polymorphism (SNP) rs73366469, located…
Abstract Number: 1962 • 2018 ACR/ARHP Annual Meeting
HLA Contributions to Risk and Protection for Anti-Centromere Autoantibody-Positive Scleroderma
Elaine F. Remmers¹, Theresa Alexander², Nadia D. Morgan³, Ami A. Shah⁴, Maureen D. Mayes⁵, Adebowale Adeyemo¹, Ayo Doumatey¹, Amy Bentley¹, Daniel Shriner⁶, Settara C Chandrasekharappa¹, Mary A. Carns⁷, Lorinda Chung⁸, Lindsey A. Criswell⁹, Chris T. Derk¹⁰, Robyn T. Domsic¹¹, Heather Gladue¹², Avram Goldberg¹³, Jessica K. Gordon¹⁴, Vivien Hsu¹⁵, Reem Jan¹⁶, Dinesh Khanna¹⁷, Thomas A. Medsger Jr.¹⁸, Paula S. Ramos¹⁹, Marcin A. Trojanowski²⁰, Lesley Ann Saketkoo²¹, Elena Schiopu²², Victoria Shanmugam²³, Benjamin D. Korman²⁴, Brynn Kron⁹, S. Louis Bridges Jr.²⁵, Kathleen D. Kolstad²⁶, Elana J. Bernstein²⁷, Suzanne Kafaja²⁸, Kathleen Maksimowicz-McKinnon²⁹, Rick Silver³⁰, Virginia D. Steen³¹, John Varga³², Charles Rotimi¹, Francesco Boin³³, Fredrick M. Wigley³⁴, Daniel L. Kastner³⁵ and Pravitt Gourh³⁶, ¹National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²National Institutes of Health, Bethesda, MD, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁶National Human Genome Research Institute, National Institutes of Health (NIH), Bethesda, MD, ⁷Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁸Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁹University of California San Francisco, San Francisco, CA, ¹⁰Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹²Rheumatology, Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ¹³NYU Langone Medical Center, New York, NY, ¹⁴Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁵Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ¹⁶Medicine, Rheumatology, University of Chicago, Chicago, IL, ¹⁷Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁸University of Pittsburgh, Pittsburgh, PA, ¹⁹Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²⁰Boston University School of Medicine, Boston, MA, ²¹Rheumatology, Tulane University School of Medicine, New Orleans, LA, ²²University of Michigan, Ann Arbor, MI, ²³Rheumatology, The George Washington University, Washington, DC, ²⁴Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ²⁵Clinical Immunology & Rheum, Univ of Alabama, Birmingham, AL, ²⁶Rheumatology, Stanford University Medical Center, Stanford, CA, ²⁷Rheumatology, Columbia University, New York, NY, ²⁸David Geffen School of Medicine, UCLA, Los Angeles, CA, ²⁹Rheumatology, Henry Ford Hospital, Detroit, MI, ³⁰Rheumatology, Medical University of SC, Charleston, SC, ³¹Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ³²Northwestern University, Chicago, IL, ³³Rheumatology, University California, San Francisco, San Francisco, CA, ³⁴Rheum Div/Mason F Lord, Johns Hopkins University, Baltimore, MD, ³⁵Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³⁶Rheumatology, NIAMS, National Institutes of Health, Bethesda, MD
Background/Purpose: Anti-nuclear autoantibodies are a hallmark of scleroderma with anti-centromere antibody (ACA) recognizing centromeric antigens. ACA-positive patients have longstanding Raynaud’s, limited cutaneous disease and increased…
Abstract Number: 1963 • 2018 ACR/ARHP Annual Meeting
Phenome Wide Association Study of IL6R Variant Identifies Drug Target for Cardiovascular Disease and Inflammation
Tianxi Cai^1,2,3, Yichi Zhang^1,3, Yuk-Lam Ho¹, Nicholas Link¹, Jiehuan Sun^1,3, Jie Huang^1,4, Tianrun Cai^1,2,4, Scott Damrauer⁵, Yuri Ahuja², Jacqueline Honerlaw¹, Jie Huang¹, Lauren Costa¹, Petra Schubert¹, Chuan Hong³, David Gagnon^1,6, Yan Sun⁷, Michael Gaziano^1,2,4, Peter Wilson^7,8, Kelly Cho^1,2,4, Philip Tsao⁹, Christopher J. O'Donnell^1,2 and Katherine P. Liao^1,2,4, ¹VA Boston Healthcare System, Boston, MA, ²Harvard Medical School, Boston, MA, ³Harvard T.H. Chan School of Public Health, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Corporal Michael Crescenz VA Medical Center, Perlman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Boston University School of Public Health, Boston, MA, ⁷Emory University Schools of Medicine and Public Health, Atlanta, GA, ⁸Atlanta VA Medical Center, Atlanta, GA, ⁹VA Palo Alto Health Care System, Department of Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Individuals with an interleukin 6 receptor (IL6R) genetic variant not on IL6R blocking therapy have biomarker profiles similar to those treated with IL6R blockers. …
Abstract Number: 1964 • 2018 ACR/ARHP Annual Meeting
Epigenetic Changes of Energy Metabolism-Related Genes in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Brian Pedersen¹, Roxana Coras^1,2, Wei Wang³, Gary S. Firestein¹ and Monica Guma^1,2, ¹Medicine, University of California San Diego, La Jolla, CA, ²Medicine, Autonomous University of Barcelona, Bellatera, Spain, ³Chemistry and Biochemistry, University of California San Diego, La Jolla, CA
Background/Purpose: Epigenetic changes contribute to the pathogenesis of rheumatoid arthritis (RA) and a comprehensive epigenomic characterization of RA fibroblast-like synoviocytes (FLS) has recently been described.…
Abstract Number: 1965 • 2018 ACR/ARHP Annual Meeting
Association of HLA Class II Alleles with Relapse and Interstitial Lung Disease in Myeloperoxidsae (MPO) -ANCA Positive Vasculitis in a Japanese Population
Aya Kawasaki¹, Ken-ei Sada², Fumio Hirano^3,4, Shigeto Kobayashi⁵, Hidehiro Yamada⁶, Hiroshi Furukawa^1,7, Kenji Nagasaka⁸, Takahiko Sugihara⁹, Kunihiro Yamagata¹⁰, Takayuki Sumida¹¹, Shigeto Tohma^12,13, Shoichi Ozaki⁶, Hiroshi Hashimoto¹⁴, Hirofumi Makino¹⁵, Yoshihiro Arimura¹⁶, Masayoshi Harigai¹⁷ and Naoyuki Tsuchiya¹, ¹University of Tsukuba, Faculty of Medicine, Molecular and Genetic Epidemiology Laboratory, Tsukuba, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Department of Rheumatology, Tokyo, Japan, ⁴Tokyo Medical and Dental UniversityGraduate School of Medical and Dental Sciences, Department of Lifetime Clinical Immunology, Tokyo, Japan, ⁵Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, ⁶St. Marianna University, School of Medicine, Department of Internal Medicine, Kawasaki, Japan, ⁷National Hospital Organization Sagamihara l Hospital, Clinical Research Center for Allergy and Rheumatology, Sagamihara, Japan, ⁸Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ⁹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹⁰University of Tsukuba, Faculty of Medicine, Department of Nephrology, Tsukuba, Japan, ¹¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ¹²National Hospital Organization Tokyo Hospital, Sagamihara, Japan, ¹³National Hospital Organization Tokyo National Hospital, Kiyose, Japan, ¹⁴Juntendo University School of Medicine, Tokyo, Japan, ¹⁵Okayama University Hospital, Okayama, Japan, ¹⁶Kyorin University School of Medicine, First Department of Internal Medicine, Tokyo, Japan, ¹⁷Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan
Background/Purpose: The high prevalence of microscopic polyangiitis (MPA) and myeloperoxidase (MPO)-ANCA positive patients as well as frequent occurrence of interstitial lung disease (ILD) constitute unique…
Abstract Number: 1966 • 2018 ACR/ARHP Annual Meeting
Transcriptome and Methylome Integrative Molecular Analysis Uncovers a New Systemic Autoimmune Disease Classification
Guillermo Barturen¹, Sepideh Babaei², Francesc Catala-Moll³, Zuzanna Makowska², Antonio García-Gómez³, Anne Buttgereit⁴, Elena Carnero-Montoro¹, Sikander Hayat⁴, Martin Kerick⁵, Thomas Charlon⁶, David C Gemperline⁷, Lucas Le Lann⁸, Rosa Quirantes-PIné⁹, Isabel Borrás-Linares¹⁰, Brian Muchmore¹, Jorge Kageyama⁴, Javier Rodríguez-Ubreva³, Alvaro Fernández-Ochoa⁹, Pedro Carmona Sanz¹¹, Christophe Jamin⁸, Ralf Lesche², Robert J. Benschop⁷, Chris Chamberlain¹², Ernst R. Dow⁷, Tania Gomes¹, Maria Juárez¹³, Laurence Laigle¹⁴, Jacqueline Marovac¹², Fiona MacDonald¹⁵, Jerome Wojcik⁶, Esteban Ballestar¹⁶, Lorenzo Beretta¹⁷, Maria Orietta Borghi¹⁸, Johan Frostegård¹⁹, Maria Luisa Garcia²⁰, Javier Martín⁵, Jacques-Olivier Pers⁸, Yves Renadineau²¹, Antonio Segura Carretero⁹ and Marta Alarcón-Riquelme^1,19, ¹Medical Genomics, Center for Genomics and Oncological Research (GENYO), Granada, Spain, ²Pharmaceuticals Division, Bayer Pharma Aktiengesellschaft, Berlin, Germany, ³Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain, ⁴Bayer Pharma Aktiengesellschaft, Berlin, Germany, ⁵Institute of Parasitology and Biomedicine López Neyra, Spanish National Research Council, Granada, Spain, ⁶QuartzBIO, SA, Geneva, Switzerland, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸U1227, Université de Brest, Inserm, Labex IGO, CHU de Brest, Brest, France, ⁹Department of Analytical Chemistry, University of Granada, Granada, Spain, ¹⁰Analytical Chemistry, University of Granada, Granada, Spain, ¹¹Unit of Bioinformatics, Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Granada, Spain, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB, Slough, United Kingdom, ¹⁴Institut de Recherches Internationales Servier, Suresnes, France, ¹⁵Bayer Pharma G, Berlin, Germany, ¹⁶Cancer Epigenetics and Biology Programme (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain, ¹⁷Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ¹⁸University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy, ¹⁹Unit for Chronic Inflammatory Diseases, Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²⁰Nano-Imaging, BIONAND. Centro Andaluz de Nanotecnología y Biomedicina, Malaga, Spain, ²¹U1227, Université de Brest, inserm, Labex IGO, CHU de brest, Brest, France
Background/Purpose: Systemic autoimmune diseases (SADs) are chronic inflammatory conditions with autoimmune aetiology and many common clinical features, difficulting diagnosis and adequate treatment decisions. Finding new…
Abstract Number: 1967 • 2018 ACR/ARHP Annual Meeting
Detection of Association of Long Noncoding RNA ATP6V0E2-AS1 Single Nucleotide Polymorphism with Susceptibility to Myeloperoxidase-ANCA Associated Vasculitis Based on Transcriptome Analysis
Yuka Iwahashi^1,2, Aya Kawasaki^1,2, Takayo Tsuchiura³, Ken-ei Sada⁴, Fumio Hirano^5,6, Daisuke Tsukui⁷, Shigeto Kobayashi⁸, Hidehiro Yamada⁹, Hiroshi Furukawa^1,2,10, Kenji Nagasaka¹¹, Takahiko Sugihara¹², Nao Nishida³, Kunihiro Yamagata¹³, Takayuki Sumida¹⁴, Shigeto Tohma^10,15, Shoichi Ozaki⁹, Hiroshi Hashimoto¹⁶, Hirofumi Makino¹⁷, Yoshihiro Arimura¹⁸, Hajime Kono¹⁹, Masayoshi Harigai²⁰ and Naoyuki Tsuchiya^1,2, ¹University of Tsukuba, Graduate School of Comprehensive Human Sciences, Masters' Program in Medical Sciences, Tsukuba, Japan, ²University of Tsukuba, Faculty of Medicine, Molecular and Genetic Epidemiology Laboratory, Tsukuba, Japan, ³Genome Medical Science Project, National Center for Global Health and Medicine, Research Center for Hepatitis and Immunology, Ichikawa, Japan, ⁴Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁵Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Department of Rheumatology, Tokyo, Japan, ⁶Tokyo Medical and Dental UniversityGraduate School of Medical and Dental Sciences, Department of Lifetime Clinical Immunology, Tokyo, Japan, ⁷Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ⁸Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, ⁹St. Marianna University, School of Medicine, Department of Internal Medicine, Kawasaki, Japan, ¹⁰National Hospital Organization Sagamihara l Hospital, Clinical Research Center for Allergy and Rheumatology, Sagamihara, Japan, ¹¹Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ¹²Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹³University of Tsukuba, Faculty of Medicine, Department of Nephrology, Tsukuba, Japan, ¹⁴Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ¹⁵National Hospital Organization Tokyo National Hospital, Kiyose, Japan, ¹⁶Juntendo University School of Medicine, Tokyo, Japan, ¹⁷Okayama University Hospital, Okayama, Japan, ¹⁸Kyorin University School of Medicine, First Department of Internal Medicine, Tokyo, Japan, ¹⁹Teikyo University School of Medicine, Department of Internal Medicine, Tokyo, Japan, ²⁰Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan
Background/Purpose: Because of the low prevalence, only three genome-wide association studies, all from the Caucasian populations, have been reported on ANCA-associated vasculitis (AAV) thus far;…
Abstract Number: 1968 • 2018 ACR/ARHP Annual Meeting
eQTL Analysis of More Than 1000 Human Blood Samples Reveals Shared and Unique Signals across Seven Systemic Autoimmune Diseases : The Precisesads Project
Martin Kerick¹, David Gonzalez Serna¹, Elena Carnero-Montoro², Sepideh Babaei³, Marialbert Acosta-Herrera¹, Maria Teruel², Guillermo Barturen², Zuzanna Makowska³, Anne Buttgereit⁴, Sikander Hayat⁴, Jorge Kageyama⁴, Manuel Martínez-Bueno², PRECISESADS Clinical Consortium⁵, Ralf Lesche³, Javier Martin⁶ and Marta Alarcón-Riquelme², ¹Institute of Parasitology and Biomedicine López-Neyra, IPBLN-CSIC, Granada, Spain, ²Medical Genomics, Center for Genomics and Oncological Research (GENYO), Granada, Spain, ³Pharmaceuticals Division, Bayer Pharma Aktiengesellschaft, Berlin, Germany, ⁴Bayer Pharma Aktiengesellschaft, Berlin, Germany, ⁵Spain, ⁶Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain., Granada, Spain
Background/Purpose: Systemic autoimmune diseases (SADs) are chronic inflammatory conditions with autoimmune aetiology and many common clinical features, hampering diagnosis and adequate treatment decisions. Finding new…
Abstract Number: 1969 • 2018 ACR/ARHP Annual Meeting
GENE Enhancers Associated with an Increase Risk of Developing JIA Fail to DOWN Regulate RUNX1 after CELL Stimulation
Annie Yarwood¹, Kate Duffus², Christopher Taylor³, Amanda McGovern², Stephen Eyre⁴ and Wendy Thomson⁵, ¹Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom, ³University of Manchester, Manchester, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: In recent years there have been tremendous strides in determining the genetic component of complex diseases, not least in Juvenile Idiopathic Arthritis (JIA). We…
Abstract Number: 1970 • 2018 ACR/ARHP Annual Meeting
Linking Genetics to T Cell Phenotype in JIA: Rationale for IL-2 Therapy
Annie Yarwood¹, Samantha Smith¹, Stephen Eyre² and Wendy Thomson³, ¹Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ³Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Several genetic regions associated with susceptibility to juvenile idiopathic arthritis (JIA), harbour genes involved in the interleukin-2 (IL-2) response which is pivotal in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].